The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Breder V.V.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Gorbunova V.A.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN

Orel N.F.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Sakaeva D.D.

GBUZ "Bashkirskiĭ respublikanskiĭ klinicheskiĭ onkologicheskiĭ dispanser", Ufa

Shabaeva M.M.

Astrakhanskiĭ oblastnoĭ onkologicheskiĭ dispanser, otdelenie khimioterapii

Orlova K.V.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Karpenko T.D.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Kuz'minov A.E.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Borisova T.A.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Bisovskaia Iu.V.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Emel'ianova G.S.

Kafedra onkologii FDPO GBOU VPO "Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet" Minzdravsotsrazvitiia Rossii

Luk'ianchenko A.B.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Results of a Russian multicenter clinical trial of Exorum/mFOLFOX6 in the first-line treatment of disseminated colon cancer

Authors:

Breder V.V., Gorbunova V.A., Orel N.F., Sakaeva D.D., Shabaeva M.M., Orlova K.V., Karpenko T.D., Kuz'minov A.E., Borisova T.A., Bisovskaia Iu.V., Emel'ianova G.S., Luk'ianchenko A.B.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2012;1(2): 42‑52

Views: 9296

Downloaded: 183

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Breder VV, Gorbunova VA, Orel NF, et al. . Results of a Russian multicenter clinical trial of Exorum/mFOLFOX6 in the first-line treatment of disseminated colon cancer. P.A. Herzen Journal of Oncology. 2012;1(2):42‑52. (In Russ.)

Подписка 2025 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Close metadata
Recommended articles:
Colo­rectal cancer and gut microbiota. P.A. Herzen Journal of Onco­logy. 2024;(2):60-66
Unco­ntrolled inhi­bition of checkpoints. P.A. Herzen Journal of Onco­logy. 2024;(2):67-73
Correction of anemia and mito­chondrial dysfunction by iron citrate «Sintezit» during neoadjuvant chemotherapy for colo­rectal cancer and lymphoproliferative diso­rders. Russian Journal of Evidence-Based Gastroenterology. 2024;(1):21-31
Gona­dotropin-releasing hormone agonists as a chance for motherhood in the future. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):30-36
D2 and D3 lymph node dissection for colon cancer. Piro­gov Russian Journal of Surgery. 2024;(7):25-35
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma. Piro­gov Russian Journal of Surgery. 2024;(10):7-20
Personalized evaluation of D3-lymph node dissection complexity for right colo­rectal cancer considering anatomy of supe­rior mese­nteric vessels. Piro­gov Russian Journal of Surgery. 2024;(10):29-37

The authors studied the efficacy and tolerability of the Russian generic agent EXORUM (oxaliplatin) in combination with calcium folinate and 5-fluoruracil (an mFOLOX6 regimen) in the first-line chemotherapy (CT) of disseminated colon cancer (DCC). In October 2008 to January 2012, the trial enrolled 40 patients (mean aged 60 years). A total of 303 courses of CT were performed. Its objective effect was recorded in 47.5% of the patients; disease stabilization of more than 8 weeks was noted in 30%. The median time to progression was 6.4 months; the median overall survival was 16.4 months. Six patients were found to have grade III-IV hematological toxicity, including a febrile neutropenic episode. Grade I, II, and III sensory neuropathy was observed in 32 (80%), 10 (25%), and 2 (5%) patients, respectively. When the first signs of neuropathy appeared, pre- and posttreatments with Ca2+ and Mg2+ preparations were performed in all patients. Thus, EXORUM demonstrated the efficacy and safety comparable to those shown in large-scale randomized trials.

Keywords:

colon cancer
chemotherapy
oxaliplatin

Authors:

Breder V.V.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Gorbunova V.A.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN

Orel N.F.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Sakaeva D.D.

GBUZ "Bashkirskiĭ respublikanskiĭ klinicheskiĭ onkologicheskiĭ dispanser", Ufa

Shabaeva M.M.

Astrakhanskiĭ oblastnoĭ onkologicheskiĭ dispanser, otdelenie khimioterapii

Orlova K.V.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Karpenko T.D.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Kuz'minov A.E.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Borisova T.A.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Bisovskaia Iu.V.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Emel'ianova G.S.

Kafedra onkologii FDPO GBOU VPO "Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet" Minzdravsotsrazvitiia Rossii

Luk'ianchenko A.B.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

List of references:

  1. Davydov M.I., Aksel' E.M., red. Statistika zlokachestvennykh novoobrazovanii v Rossii i stranakh SNG v 2008 g. Vestnik RONTs im. N.N. Blokhina RAMN. 2010; 21 (2, pril. 1).
  2. Scheithauer W., Rosen H., Kornek G.V. et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. 1993; 306: 752-5.
  3. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J. Clin. Oncol. 1992; 10: 904-11.
  4. Grothey A., Goldberg R.M. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin. Pharmacother. 2004; 5: 2159-70.
  5. Machover D., Diaz-Rubio E., de Gramont A. et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 1996; 7: 95-8.
  6. Cvitkovic E., Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin. Oncol. 1999; 26: 647-62.
  7. De Gramont A., Vignoud J., Tournigand C. et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer. 1997; 33: 214-9.
  8. Andre T., Louvet C., Raymond E. et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol. 1998; 9: 1251-3.
  9. Andre T., Bensmaine MA., Louvet C. et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol. 1999; 17: 3560-8.
  10. Tournigand C., Andre T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004; 22: 229-37.
  11. Goldberg R.M., Sargent D.J., Morton R.F. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004; 22: 23-30.
  12. De Gramont A., Figer A., Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000; 18: 2938-47.
  13. Nordlinger B., Sorbye H., Glimelius B. et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371: 1007-16.
  14. Adam R., Delvart V., Pascal G. et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg. 2004; 240: 644-57; discussion 657-8.
  15. WHO. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.
  16. NCI CTC v.2 National Cancer Institute. Common toxicity criteria (version 2). http: //ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv2nom-4-30-99-fi nal3.pdf
  17. Kohne C.H., Cunningham D., Di C.F. et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann. Oncol. 2002; 13: 308-17.
  18. Cassidy J., Misset J.L. Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. 2002; 29: 11-20.
  19. Gamelin R. et al. Prevention of Oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients, receiving Oxaliplatin combined with 5-Fluorouracil and Leucovorin for advanced colorectal cancer. Clin. Cancer Res. 2004; 10: 4055-61.
  20. Grothey A., Nikcevich D.A., Sloan J.A. et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J. Clin. Oncol. 2011; 29: 421-7.
  21. Gamelin L., Capitain O., Morel A. et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin. Cancer Res. 2007; 13: 6359-68.
  22. Lecomte T., Landi B., Beaune P. et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin. Cancer Res. 2006; 12: 3050-6.
  23. Webster R.G., Brain K.L., Wilson R.H. et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 2005; 146: 1027-39.
  24. Park S.B., Goldstein D., Lin C.S. et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J. Clin. Oncol. 2009; 27: 1243-9.
  25. Pendyala L., Creaven P.J., Perez R. et al. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother. Pharmacol. 1995; 36: 271-8.
  26. Cascini S., Catalano V., Cardella L. et al. Neuroprotective effect of reduced Glutathione on Oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2002; 20: 3478-83.
  27. Fournier J., Steinberg R., Gauthier T. et al. Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience. 1993; 55: 629-41.
  28. Dold F., Hoey D., Carberry M., Musket A., Friedberg V., Mitchell E. Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin. Proc. ASCO. 2002; 1478 (abstr.).
  29. Chibaudel B., Bonnetain F., Tournigand C. et al. Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study. The Oncologist. 2011; 16: 1228-38.
  30. Ducreux M., Malka D., Mendiboure J. et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FF CD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol. 2011; 12: 1032-44.
  31. De Gramont A., Buyse M., Abrehamantes J.C. et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J. Clin. Oncol. 2007; 25: 3224-29.
  32. Adams R., Meade A., Seymour M. et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011; 12: 642-53.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.